Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Reports Strong Progress in ESG Focus Areas
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Fourth-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback